Who was studied, and how
Two numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 23 other studies
8,179people in the Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease trial, from 2011
8,175of them with cardiovascular disease, in this paper
Among LDL-C <55 mg/dL, the trial randomly assignedassigned by chance
icosapent ethyl
placebo
May have lowered primary composite end point−34%
randomised · one subgroupthe abstract, start to end
… in the placebo group (hazard ratio [HR], 0.66 [95% CI, 0.50-0.87]; absolute risk reduction, 6.6%; CONCLUSIONS: Among …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Primary composite end pointicosapent ethyl vs placebo, in LDL-C <55 mg/dL
HR 0.660.50–0.87
Primary composite end pointicosapent ethyl vs placebo, in LDL-C <55 mg/dL
−6.60
Other lipid agentsLipids
Other lipid agents × lipidshelps?mixed
unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
1 / 7